Statement: All 4 of the CHF cases in the primary trial, were in cohort 1.
Primary_evidence: Adverse Events 1:   Total: 12/32 (37.50%)   Anaemia 0/32 (0.00%)   Neutropenia 1/32 (3.13%)   Thrombocytopenia 4/32 (12.50%)   Atrial fibrillation 1/32 (3.13%)   Cardiac failure congestive 1/32 (3.13%)   Myocardial ischaemia 1/32 (3.13%)   Abdominal discomfort 0/32 (0.00%)   Ascites 1/32 (3.13%)   Constipation 0/32 (0.00%)   Rectal haemorrhage 1/32 (3.13%)   Vomiting 1/32 (3.13%)   Fatigue 1/32 (3.13%) Adverse Events 2:   Total: 8/20 (40.00%)   Anaemia 1/20 (5.00%)   Neutropenia 0/20 (0.00%)   Thrombocytopenia 1/20 (5.00%)   Atrial fibrillation 0/20 (0.00%)   Cardiac failure congestive 0/20 (0.00%)   Myocardial ischaemia 0/20 (0.00%)   Abdominal discomfort 1/20 (5.00%)   Ascites 0/20 (0.00%)   Constipation 2/20 (10.00%)   Rectal haemorrhage 0/20 (0.00%)   Vomiting 0/20 (0.00%)   Fatigue 0/20 (0.00%)